Immunomics in skin cancer - improvement in diagnosis, prognosis and therapy monitoring

Current Proteomics

Volumn 10, Issue 3, 2013, Pages 202-217

  Bulman, Amanda ^a   Neagu, Monica ^b   Constantin, Carolina ^b  

^a BRUKER DALTONIK GMBH   (Germany)

^b VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

Author keywords

Basal cell carcinoma; Immunomics; Lymphoma; Melanoma; Squamous cell carcinoma

Indexed keywords

ADAPTIVE IMMUNITY; BASAL CELL CARCINOMA; CANCER IMMUNOLOGY; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL POPULATION; CUTANEOUS MELANOMA; DENDRITIC CELL; DERMATITIS; ENDOTHELIUM CELL; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KERATINOCYTE; MACROPHAGE; MAST CELL; MELANOMA SKIN CANCER; MEMORY T LYMPHOCYTE; MERKEL CELL TUMOR; MONOCYTE; NATURAL KILLER CELL; NON MELANOMA SKIN CANCER; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SKIN CARCINOGENESIS; SKIN LYMPHOMA; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84893018865     PISSN: 15701646     EISSN: None     Source Type: Journal    
DOI: 10.2174/1570164611310030003     Document Type: Review

References (101)

1. Braga-Neto, U. M. and Marques, E. T. Jr. From functional genomics to functional immunomics: new challenges, old problems, big rewards. PLoS Comput. Biol., 2006, 2(7), e81, 0651-0662.
2. Sette, A.; Fleri, W.; Peters, B.; Sathiamurthy, M.; Bui, H. H. and Wilson, S. A roadmap for the immunomics of category A-C pathogens. Immunity, 2005, 22, 155-161.
3. Brusic, V. From immunoinformatics to immunomics. J. Bioinform. Comput. Biol., 2003, 1, 179-181.
4. Shurin, M. R.; Umansky, V. and Malyguine, A. The Tumor Immunoenvironment, Springer, 2013.
5. Blumenberg, M. SKINOMICS: Transcriptional profiling in dermatology and skin biology. Curr. Genomics, 2012, 13(5), 363-368.
6. Debenedictis, C.; Joubeh, S.; Zhang, G.; Barria, M. and Ghohestani, R. F. Immune functions of the skin. Clin. Dermatol., 2001, 19, 573-585.
7. Bos, J. D. Skin Immune System: Cutaneous Immunology and clinical immunodermatology, 3rd ed.; CRC Press, Boca Raton: New York, 2005.
8. Woods, G. M.; Malley, R. C. and Muller, H. K. The skin immune system and the challenge of tumour immunosurveillance. Eur. J. Dermatol., 2005, 15(2), 63-69.
9. Dahl, M. V. Clinical Immunodermatology, 3rd ed.; Mosby: New York, 1996.
10. Kupper, T. S. and Fuhlbrigge, R. C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat. Rev. Immunol., 2004, 4(3), 211-222.
11. Peters, J. H.; Tjabringa, G. S.; Fasse, E.; de Oliveira, V. L.; Schalkwijk, J.; Koenen, H. J. and Joosten, I. Co-culture of healthy human keratinocytes and T-cells promotes keratinocyte chemokine production and RORgt-positive IL-17 producing T-cell populations. J. Dermatol. Sci., 2013, 69(1), 44-53.
12. Dinarello, C. A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol., 1998, 16, 457-499.
13. Yano, S.; Banno, T.; Walsh, R. and Blumenberg, M. Transcriptional responses of human epidermal keratinocytes to cytokine interleukin-1. J. Cell. Physiol., 2008, 214, 1-13.
14. Steinhoff, M.; Brzoska, T. and Luger, T. A. Keratinocytes in epidermal immune responses. Curr. Opin. Allergy Clin. Immunol., 2001, 1, 469-476.
15. Wong, C. H. Y.; Heit, B. and Kubes, P. Molecular regulators of leukocyte chemotaxis during inflammation. Cardiovasc. Res., 2010, 86, 183-191.
16. rd and Fairchild, R. L. Hapten application to the skin induces an inflammatory program directing hapten-primed effector CD8 T cell interaction with hapten-presenting endothelial cells. J. Immunol., 2011, 186(4), 2117-2126.
17. Robert, C. and Kupper, T. S. Inflammatory skin diseases, T cells, and immune surveillance. N. Engl. J. Med., 1999, 341, 1817-1828.
18. Neagu, M. The immune system-a hidden treasure for biomarker discovery in cutaneous melanoma. Adv Clin Chem., 2012, 58, 89-140.
19. Xiong, N.; Fu, Y.; Hu, S.; Xia, M. and Yang, J. CCR10 and its ligands in regulation of epithelial immunity and diseases. Protein Cell., 2012, 3(8), 571-580.
20. Weber, M.; Hauschild, R.; Schwarz, J.; Moussion, C.; de Vries, I.; Legler, D. F.; Luther, S. A.; Bollenbach, T. and Sixt, M. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science, 2013, 339(6117), 328-332.
21. Bennett, M. F.; Robinson, M. K.; Baron, E. D. and Cooper, K. D. Skin immune systems and inflammation: protector of the skin or promoter of aging? J. Investig. Dermatol. Symp. Proc., 2008, 13(1), 15-19.
22. Sarchio, S. N.; Kok, L. F.; O'Sullivan, C.; Halliday, G. M. and Byrne, S. N. Dermal mast cells affect the development of sunlightinduced skin tumours. Exp. Dermatol., 2012, 21(4), 241-248.
23. Carreau, A.; Kieda, C. and Grillon, C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp. Cell. Res., 2011, 317(1), 29-41.
24. Muller, H. K.; Bucana, C. D. and Kripke, M. L. Antigen presentation in the skin: modulation by u. v. radiation and chemical carcinogens. Semin. Immunol., 1992, 4, 205-215.
25. Schlecker, E.; Stojanovic, A.; Eisen, C.; Quack, C.; Falk, C. S.; Umansky, V. and Cerwenka, A. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol., 2012, 189(12), 5602-5611.
26. Zhang, R.; Huynh, A.; Whitcher, G.; Chang, J.; Maltzman, J. S. and Turka, L. A. An obligate cell-intrinsic function for CD28 in Tregs. J. Clin. Invest., 2013, 123(2), 580-593.
27. Di Piazza, M.; Nowell, C. S.; Koch, U.; Durham, A. D. and Radtke, F. Loss of cutaneous TSLP-dependent immune responses skews the balance of inflammation from tumor protective to tumor promoting. Cancer Cell, 2012, 22(4), 479-493.
28. Chan, J. K.; Roth, J.; Oppenheim, J. J.; Tracey, K. J.; Vogl, T.; Feldmann, M.; Horwood, N. and Nanchahal, J. Alarmins: awaiting a clinical response. J. Clin. Invest., 2012, 22(8), 2711-2719.
29. Moseley, T. A.; Haudenschild, D. R.; Rose, L. and Reddi, A. H. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev., 2003, 14(2), 155-174.
30. He, D.; Li, H.; Yusuf, N.; Elmets, C. A.; Athar, M.; Katiyar, S. K. and Xu, H. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PloS One, 2012, 7(2), e32126, 1-9.
31. Stelkovics, E.; Kiszner, G.; Meggyeshazi, N.; Korom, I.; Varga, E.; Nemeth, I.; Molnar, J.; Marczinovits, I. and Krenacs, T. Selective in situ protein expression profiles correlate with distinct phenotypes of basal cell carcinoma and squamous cell carcinoma of the skin. Histol. Histopathol., 2013, 28(7), 941-954.
32. Zaiss, D. M. W.; Loosdregt, J. van.; Gorlani, A.; Bekker, C. P. J.; Gröne, A.; Sibilia, M.; van Bergen en Henegouwen, P. M. P.; Roovers, R. C.; Coffer, P. J. and Sijts, A. J. A. M. Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor. Immunity, 2013, 38(2), 275-284.
33. Dellon, A. L.; Potvin, C.; Chretien, P. B. and Rogentine, C. N. The immunobiology of skin cancer. Plast. Reconstr. Surg., 1975; 55(3), 341-354.
34. Myskowski, P. L. and Safai, B. The immunology of basal cell carcinoma. Int. J. Dermatol., 1988, 27, 601-607.
35. Elsasser-Beile, U.; von Kleist, S.; Stahle, W.; Schurhammer-Fuhrmann, C.; Mönting, J. S. and Gallati, H. Cytokine levels in whole blood cell cultures as parameters of the cellular immunologic activity in patients with malignant melanoma and basal cell carcinoma. Cancer, 1993, 71, 231-236.
36. Habets, J. M.; Tank, B.; Vuzevski, V. D.; van Reede, E. C.; Stolz, E. and van Joost, T. Characterization of the mononuclear infiltrate in basal cell carcinoma: a predominantly T cell-mediated immune response with minor participation of Leu-7+ (Natural Killer) cells and Leu-14+(B) cells. J. Invest. Dermatol., 1988, 90, 289-292.
37. De Giorgi, V.; Salvini, C.; Chiarugi, A.; Paglierani, M.; Maio, V.; Nicoletti, P.; Santucci, M.; Carli, P. and Massi, D. In vivo characterization of the inflammatory infiltrate and apoptotic status in imiquimod-treated basal cell carcinoma. Int. J. Dermatol., 2009, 48(3), 312-321.
38. Sakaguchi, S.; Wing, K.; Onishi, Y.; Prieto-Martin, P. and Yamaguchi, T. Regulatory T cells: how do they suppress immune responses? Int. Immunol., 2009, 21, 1105-1111.
39. Kaporis, H. G.; Guttman-Yassky, E.; Lowes, M. A.; Haider, A. S.; Fuentes-Duculan, J.; Darabi, K.; Whynot-Ertelt, J.; Khatcherian, A.; Cardinale, I.; Novitskaya, I.; Krueger, J. G. and Carucci, J. A. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J. Invest. Dermatol., 2007, 127, 2391-2398.
40. Tjiu, J. W.; Chen, J. S.; Shun, C. T.; Lin, S. J.; Liao, Y. H.; Chu, C. Y.; Tsai, T. F.; Chiu, H. C.; Dai, Y. S.; Inoue, H.; Yang, P. C.; Kuo, M. L. and Jee, S. H. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J. Invest. Dermatol., 2009, 129, 1016-1025.
41. Kooy, A. J. W. Cellular and immunological aspects of basal cell carcinoma. PhD thesis, ISBN 90·9012037·8, 1998.
42. Fagundes, C. P.; Glaser, R.; Johnson, S. L.; Andridge, R. R.; Yang, E. V.; Di Gregorio, M. P.; Chen, M.; Lambert, D. R.; Jewell, S. D.; Bechtel, M. A.; Hearne, D. W.; Herron, J. B. and Kiecolt-Glaser, J. K. Basal cell carcinoma: stressful life events and the tumor environment. Arch. Gen. Psychiatry, 2012, 69(6), 618-626.
43. Gehad, A. E.; Lichtman, M. K.; Schmults, C. D.; Teague, J. E.; Calarese, A. W.; Jiang, Y.; Watanabe, R. and Clark, R. A. Nitric oxideproducing myeloid-derived suppressor cells inhibit vascular E selectin expression in human squamous cell carcinomas. J. Invest. Dermatol., 2012, 132(11), 2642-2651.
44. Black, A. P. and Ogg, G. S. The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin. Exp. Immunol., 2003, 132(3), 379-384.
45. Moch, C.; Moysan, A.; Lubin, R.; de la Salmonière, P.; Soufir, N.; Galisson, F.; Vilmer, C.; Venutolo, E.; Le Pelletier, F.; Janin, A. and Basset-Séguin, N. Divergence between the high rate of p53 mutations in skin carcinomas and the low prevalence of anti-p53 antibodies. Br. J. Cancer., 2001, 85, 1883-1886.
46. Vierboom, M. P.; Zwaveling, S.; Bos, G. M. J.; Ooms, M.; Krietemeijer, G. M.; Melief, C. J. and Offringa, R. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res., 2000, 60, 5508-5513.
47. Patel, A.; Halliday, G. M. and Barnetson, R. S. CD4+ T lymphocyte infiltration correlates with regression of a UV-induced squamous cell carcinoma. J. Dermatol. Sci., 1995, 9, 12-19.
48. Erb, P.; Ji, J.; Wernli, M.; Kump, E.; Glaser, A. and Büchner, S. A. Role of apoptosis in basal cell and squamous cell carcinoma formation. Immunol. Lett., 2005, 100(1), 68-72.
49. Berger, C. L.; Heald, P.; Girardi, M. and Edelson, R. L. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. G. Ital. Dermatol. Venereol., 2008, 143(1), 43-54.
50. Wong, H. K.; Mishra, A.; Hake, T. and Porcu, P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br. J. Haematol., 2011, 155(2), 150-166.
51. Dummer, R.; Goldinger, S. M.; Cozzio, A.; French, L. E. and Karpova, M. B. Cutaneous lymphomas: molecular pathways leading to new drugs. J. Invest. Dermatol., 2012, 132(3 Pt 1), 517-525.
52. Schwingshackl, P.; Obermoser, G.; Nguyen, V. A.; Fritsch, P.; Sepp, N. and Romani, N. Distribution and maturation of skin dendritic cell subsets in two forms of cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome. Acta Derm. Venereol., 2012, 92(3), 269-275.
53. Campbell, J. J.; Clark, R. A.; Watanabe, R. and Kupper T. S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood, 2010, 116, 767-771.
54. Chang, D. K.; Sui, J.; Geng, S.; Muvaffak, A.; Bai, M.; Fuhlbrigge, R. C.; Lo, A.; Yammanuru, A.; Hubbard, L.; Sheehan, J.; Campbell, J. J.; Zhu, Q.; Kupper, T. S. and Marasco, W. A. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol. Cancer. Ther., 2012, 11(11), 2451-2461.
55. Agelli, M.; Clegg, L. X.; Becker, J. C. and Rollison, D. E. The etiology and epidemiology of merkel cell carcinoma. Curr. Probl. Cancer., 2010, 34(1), 14-37.
56. Feng, H.; Shuda, M.; Chang, Y. and Moore, P. S. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science, 2008, 319, 1096-1100.
57. Wooff, J. C.; Trites, J. R.; Walsh, N. M. G. and Bullock, M. J. Complete spontaneous regression of metastatic merkel cell carcinoma: a case report and review of the literature. Am. J. Dermatopathol., 2010, 32(6), 614-617.
58. Carter, J. J.; Paulson, K. G.; Wipf, G. C.; Miranda, D.; Madeleine, M. M.; Johnson, L. G.; Lemos, B. D.; Lee, S.; Warcola, A. H.; Iyer, J. G.; Nghiem, P. and Galloway, D. A. Association of Merkel cell polyomavirus-specific antibodies with Merkel cell carcinoma. J. Natl. Cancer Inst., 2009, 101, 1510-1522.
59. Touze, A.; Le Bidre, E.; Laude, H.; Fleury, MJ; Cazal, R.; Arnold, F.; Carlotti, A.; Maubec, E.; Aubin, F.; Avril, M. F.; Rozenberg, F.; Tognon, M.; Maruani, A.; Guyetant, S.; Lorette, G., and Coursaget P. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J. Clin. Oncol., 2011, 29(12), 1612-1619.
60. Paulson, K. G.; Carter, J. J.; Johnson, L. G.; Cahill, K. W.; Iyer, J. G.; Schrama, D.; Becker, J. C.; Madeleine, M. M.; Nghiem, P. and Galloway, D. A. Antibodies to Merkel cell polyomavirus T-antigen on coproteins reflect tumor burden in Merkel cell carcinoma patients. Cancer Res., 2010, 70(21), 8388-8397.
61. Paulson, K. G.; Iyer, J. G.; Tegeder, A. R.; Thibodeau, R.; Schelter, J.; Koba, S.; Schrama, D.; Simonson, W. T.; Lemos, B. D.; Byrd, D. R.; Koelle, D. M.; Galloway, D. A.; Leonard, J. H.; Madeleine, M. M.; Argenyi, Z. B.; Disis, M. L.; Becker, J. C.; Cleary, M. A. and Nghiem, P. Transcriptome wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol., 2011, 29(12), 1539-1546.
62. Ullrich, S. E. Mechanisms underlying UV-induced immune suppression. Mutat. Res., 2005, 571, 185-205.
63. Jackson, S. R.; Berrien-Elliott, M. M.; Meyer, J. M.; Wherry, E. J. and Teague, R. M. CD8(+) T Cell Exhaustion During Persistent Viral Infection is Regulated Independently of the Virus-Specific T Cell Receptor. Immunol. Invest., 2013, 42(3), 204-220.
64. Dowlatshahi, M.; Huang, V.; Gehad, A. E.; Jiang, Y.; Calarese, A.; Teague, J. E.; Dorosario, A. A.; Cheng, J.; Nghiem, P.; Schanbacher, C. F.; Thakuria, M.; Schmults, C. D.; Wang, L. C. and Clark, R. A. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T cell exhaustion in reducing T cell responses. J. Invest. Dermatol., 2013, 133(7), 1879-1889.
65. Bolstad, A. I.; Eiken, H. G.; Rosenlund, B.; Alarcón-Riquelme, M. E. and Jonsson, R. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjögren's syndrome. Arthritis Rheum., 2003, 48(1), 174-185.
66. Rabinovich, G. A.; Gabrilovich, D. and Sotomayor, E. M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 2007, 25, 267-296.
67. Reiman, J. M.; Kmieciak, M.; Manjili, M. H. and Knutson, K. L. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol., 2007, 17(4), 275-287.
68. Zattra, E.; Fortina, A. B.; Bordignon, M.; Piaserico, S. and Alaibac, M. Immunosuppression and melanocyte proliferation. Melanoma Res., 2009, 19(2), 63-68.
69. Gajewski, T. F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res., 2007, 13(18 Pt 1), 5256-5261.
70. Ilkovitch, D. and Lopez, D. M. Immune modulation by melanomaderived factors. Exp. Dermatol., 2008, 17(12), 977-985.
71. Loser, K.; Brzoska, T.; Oji, V.; Auriemma, M.; Voskort, M.; Kupas, V.; Klenner, L.; Mensing, C.; Hauschild, A.; Beissert, S. and Luger, T. A. The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans. PloS ONE, 2010, 5(2), e8958, 1-12.
72. Burdelya, L.; Kujawski, M.; Niu, G.; Zhong, B.; Wang, T.; Zhang, S.; Kortylewski, M.; Shain, K.; Kay, H.; Djeu, J.; Dalton, W.; Pardoll, D.; Wei, S. and Yu, H. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol., 2005, 174(7), 3925-3931.
73. Hussein, M. R. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int. J. Exp. Pathol., 2006, 87(3), 163-176.
74. Neagu, M.; Constantin, C. and Tanase, C. Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma. Expert Rev. Mol. Diagn., 2010, 10 (7), 897-919.
75. Scott, D. K.; Lord, R.; Muller, H. K.; Malley, R. C. and Woods, G. M. Proteomics identifies enhanced expression of stefin A in neonatal murine skin compared with adults: functional implications. Br. J. Dermatol., 2007, 156(6), 1156-1162.
76. Magister, S. and Kos, J. Cystatins in immune system. J. Cancer., 2013, 4(1), 45-56.
77. Forgber, M.; Gellrich, S.; Sharav, T.; Sterry, W. and Walden, P. Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma. PloS One., 2009, 4(12), e8376, 1-12.
78. Greco, M.; Mitri, M. D.; Chiriacò, F.; Leo, G.; Brienza, E. and Maffia, M. Serum proteomic profile of cutaneous malignant melanoma and relation to cancer progression: association to tumor derived alpha-N acetylgalactosaminidase activity. Cancer Lett., 2009, 283(2), 222-229.
79. Jeffery, L. E.; Wood, A. M.; Qureshi, O. S.; Hou, T. Z.; Gardner, D.; Briggs, Z.; Kaur, S.; Raza, K. and Sansom, D. M. Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. J. Immunol., 2012, 189(11), 5155-5164.
80. Muller, H. K.; Malley, R. C.; McGee, H. M.; Scott, D. K.; Wozniak, T. and Woods, G. M. Effect of UV radiation on the neonatal skin immune system-implications for melanoma. Photochem. Photobiol., 2008, 84(1), 47-54.
81. Tsoka, S.; Ainali, C.; Karagiannis, P.; Josephs, D. H.; Saul, L.; Nestle, F. O. and Karagiannis, S. N. Toward prediction of immune mechanisms and design of immunotherapies in melanoma. Crit. Rev. Biomed. Eng., 2012, 40(4), 279-294.
82. Minutilli, E. and Feliciani, C. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors. Tumori., 2012, 98(2), 185-190.
83. Lo, R. S. Melanoma prognostics and personalized therapeutics at a crossroad. J. Invest. Dermatol., 2013, 133(2), 292-295.
84. Muccioli, M.; Longstaff, C. and Benencia, F. Absence of CD4 Tcell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma. Immunotherapy, 2012, 5, 477-481.
85. Lotem, M.; Merims, S.; Frank, S.; Ospovat, I. and Peretz, T. Ctla-4 blockade: a new hope for the immunotherapy of malignant melanoma. Harefuah., 2012, 151(10), 585-588.
86. McArthur, G. A. and Ribas, A. Targeting oncogenic drivers and the immune system in melanoma. J. Clin. Oncol., 2013, 31(4), 499-506.
87. Goding, S. R.; Wilson, K. A.; Xie, Y.; Harris, K. M.; Baxi, A.; Akpinarli, A.; Fulton, A.; Tamada, K.; Strome, S. E. and Antony, P. A. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J. Immunol., 2013, 190(9), 4899-4909.
88. Thumar, J.; Giesen, E. and Kluger, H. M. Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers. Med., 2012, 5, 139-148.
89. Neagu, M.; Constantin, C.; Manda, G. and Margaritescu, I. Biomarkers of metastatic melanoma. Biomark. Med., 2009, 3(1), 71-89.
90. Kostalevskaia, A. V.; Petrunin, D. D.; Romadanova, N. B.; Snarskaia, E. S.; Pal'tsev, M. A. and Suchkov, S. V. The current concept of immunological disorders in the case of basal-cell carcinoma. Arkh. Patol., 2008, 70(5), 42-46.
91. Petrunin, D. D.; Okovity, S. V.; Kostalevskaia, A. V. and Suchkov, S. V. Aproaches to immunotherapy in different immunophenotypes of cutaneous basal cell carcinoma. Vopr. Onkol., 2012, 58(3), 406-412.
92. Katz, C.; Levy-Beladev, L.; Rotem-Bamberger, S.; Rito, T.; Rüdiger, S. G. and Friedler, A. Studying protein-protein interactions using peptide arrays. Chem. Soc. Rev., 2011, 40(5), 2131-2145.
93. Ge, X.; Gebe, J. A.; Bollyky, P. L.; James, E. A.; Yang, J.; Stern, L. J. and Kwok, W. W. Peptide-MHC cellular microarray with innovative data analysis system for simultaneously detecting multiple CD4 T-cell responses. PLoS One., 2010, 5(6), e11355, 1-11.
94. Letarte, S.; Brusniak, M. Y.; Campbell, D.; Eddes, J.; Kemp, C. J.; Lau, H.; Mueller, L.; Schmidt, A.; Shannon, P.; Kelly-Spratt, K. S.; Vitek, O.; Zhang, H.; Aebersold, R. and Watts, J. D. Differential plasma glycoproteome of p19 skin cancer mouse model using the Corra label-free LC-MS proteomics platform. Clin. Proteomics., 2008, 4(3-4), 105.
95. Dib, H.; Chafey, P.; Clary, G.; Federici, C.; Le Gall, M.; Dwyer, J.; Gavard, J.; Tamas, N.; Bussone, G.; Broussard, C.; Camoin, L.; Witko-Sarsat, V.; Tamby, M. C. and Mouthon, L. Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition. Proteomics., 2012, 12(15-16), 2547-2555.
96. Muller, H. K. and Woods, G. M. Ultraviolet radiation effects on the proteome of skin cells. Adv. Exp. Med. Biol., 2013, 990, 111-119.
97. Bertrand-Vallery, V.; Belot, N.; Dieu, M.; Delaive, E.; Ninane, N.; Demazy, C.; Raes, M.; Salmon, M.; Poumay, Y.; Debacq-Chainiaux, F. and Toussaint, O. Proteomic profiling of human keratinocytes undergoing UVB-induced alternative differentiation reveals TRIpartite Motif Protein 29 as a survival factor. PloS One, 2010, 5(5), e10462, 1-13.
98. de Visser, K. E.; Eichten, A. and Coussens, L. M. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer, 2006, 6, 24-37.
99. Carretero, M.; Escámez, M. J.; Prada, F.; Mirones, I.; García, M.; Holguín, A.; Duarte, B.; Podhajcer, O.; Jorcano, J. L.; Larcher, F. and Del Río, M. Skin gene therapy for acquired and inherited disorders. Histol. Histopathol., 2006, 21(11), 1233-1247.
100. Schonbach, C. From immunogenetics to immunomics. Functional prospecting of genes and transcripts. Novartis Found. Symp., 2003; 254: 177-188.
101. Grant, M. M.; Scheel-Toellner, D. and Griffiths, H. R. Contributions to our understanding of T cell physiology through unveiling the T cell proteome. Clin. Exp. Immunol., 2007, 149, 9-15.